Latest news with #OncologicDrugsAdvisoryCommittee
Business Wire
3 days ago
- Business
- Business Wire
URGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP UroGen class action lawsuit. Captioned , 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen and certain of UroGen's top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the UroGen class action lawsuit, please provide your information here: CASE ALLEGATIONS: UroGen engages in the development and commercialization of solutions for specialty cancers. According to the complaint, UroGen's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. The UroGen class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) UroGen's ENVISION clinical study for UGN-102 was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (ii) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (iii) UroGen failed to heed the U.S. Food and Drug Administration's ('FDA') warnings about the study design used to support a new drug application ('NDA') for UGN-102; and (iv) as a result, there was a substantial risk that the NDA for UGN-102 would not be approved. The UroGen class action lawsuit further alleges that on May 16, 2025, the FDA published a briefing document in advance of its Oncologic Drugs Advisory Committee meeting regarding UroGen's NDA for UGN-102, which stated that '[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret,' and that the FDA had 'recommended a randomized trial design to the Applicant several times during their product's development due to concerns with interpreting efficacy results' but UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock fell nearly 26%, according to the complaint. Then, on May 21, 2025, the UroGen class action lawsuit further alleges that the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk of the investigation therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock fell nearly 45%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired UroGen securities during the Class Period to seek appointment as lead plaintiff in the UroGen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the UroGen class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the UroGen class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the UroGen class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Yahoo
25-05-2025
- Business
- Yahoo
US FDA Votes in Favor of Benefit-Risk Profile of Johnson & Johnson's DARZALEX FASPRO
On May 20, Johnson & Johnson (NYSE:JNJ) announced that the FDA Oncologic Drugs Advisory Committee/ODAC voted 6-2 in favor of the benefit-risk profile of single-agent DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adult patients with high-risk smoldering multiple myeloma (HR-SMM). This recommendation is a step towards potentially making DARZALEX FASPRO the first treatment to delay or prevent the progression of this condition to active multiple myeloma. A closeup of pills in a pharmacy, representing the high quality medications of the company. An application for this approval was submitted to the FDA in November 2024. Currently, there are no approved treatments specifically for HR-SMM. The ODAC's decision was based on data from the Phase 3 AQUILA study. This was a randomized and open-label trial that evaluated the efficacy and safety of DARZALEX FASPRO versus active monitoring in HR-SMM patients. Smoldering multiple myeloma is an asymptomatic intermediate stage of multiple myeloma. However, ~50% of patients with HR-SMM are likely to develop active disease within 2 to 3 years. The current standard of care for SMM is active monitoring, which can lead to therapeutic intervention only after the detection of end-organ damage. Multiple myeloma is a blood cancer affecting plasma cells in the bone marrow, and it remains incurable. DARZALEX FASPRO received US FDA approval in May 2020 and is currently approved for 9 indications in multiple myeloma, including 4 for frontline treatment. Johnson & Johnson (NYSE:JNJ) engages in the R&D, manufacture, and sale of various products in the healthcare field worldwide. In August 2012, Janssen Biotech Inc. (a subsidiary of Johnson & Johnson) and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture, and commercialize daratumumab. This is the active ingredient in DARZALEX FASPRO. While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Medscape
22-05-2025
- Business
- Medscape
FDA Advisory: Daratumumab Wins, Glofitamab Loses
Daratumumab and hyaluronidase (Darzalex Faspro, Johnson & Johnson) came a step closer to being approved for high-risk smoldering multiple myeloma (SMM) on Tuesday after the Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration (FDA) voted that the benefits outweigh the risks. However, the prospects of glofitamab (Columvi, Roche) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) dimmed after the committee agreed with the FDA that the results of a trial, which was conducted largely in Asia, are not really applicable to patients in the United States. Daratumumab and hyaluronidase (DARA SC) is already on the US market as a standard first-line option for MM, but there's currently no approved medication for SMM, an MM precursor. Standard treatment for SMM is either watchful waiting or referral to a clinical trial. Glofitamab, meanwhile, has accelerated approval as monotherapy in the third or later lines for R/R DLBCL. Roche was hoping to move it to an earlier line of treatment in combination with gemcitabine and oxaliplatin for transplant-ineligible disease. The FDA called the hearing because it had concerns about the trials supporting the two applications, AQUILA in the case of DARA SC and STARGLO for glofitamab. STARGLO in the United States STARGLO evaluated substituting glofitamab for rituximab on a background of gemcitabine and oxaliplatin for transplant-ineligible R/R DLBCL, not otherwise specified, following at least one line of systemic therapy. There was a statistically significant improvement in overall survival (OS), progression-free survival (PFS), and complete response (CR) with glofitamab across 274 patients. The main concern the FDA had with the trial is that almost half of the patients were from Korea, Taiwan, and China, and there were only 25 US patients. Others came from Europe and Australia. When the FDA compared outcomes of Asian vs non-Asian patients, it found significant differences. Despite a strong hazard ratio (HR) for OS benefit in Asia (HR, 0.39), there was a trend toward worse OS in Europe and the United States and in White patients, with similar trends for worse PFS and CR rates. The reasons aren't clear. 'FDA is concerned by the lack of internal consistency observed in the STARGLO trial and how the results of the Asian region appear to be driving the overall trial results,' the agency said in meeting documents. 'The low enrollment of patients in the US limits the agency's ability to assess the applicability of the study results to a US patient population,' the FDA said in meeting documents. 'Furthermore, the FDA has identified multiple differences in patient-related, disease-related, and healthcare system–related factors between the non-Asian and Asian regional subgroup populations. Taken together, these issues raise uncertainty as to whether the results…are generalizable and applicable to a US patient population,' the agency said. Among other concerns, the FDA also noted that rituximab/gemcitabine/oxaliplatin wasn't a good comparator arm for US patients because the regimen is not commonly used in the United States, which might have contributed to low enrollment at US study sites. Trial sponsor Roche highlighted the overall outcomes and that there's an unmet need for additional DLBCL treatment options. Company representatives also said that outside of Asia, patients on glofitamab had a higher risk for disease than those on rituximab, and rituximab patients were more likely to subsequently receive new anti-lymphoma therapy like CAR T cells. It pinned the low US enrollment on COVID disruptions during the pandemic. In the end, ODAC sided with the agency, voting 8 to 1 that the trial results are not applicable to US patients. Echoing many committee members, panelist Heidi McKean, MD, community oncologist in Sioux Falls, South Dakota, said she voted that the trials wasn't applicable 'due to the inconsistencies in the results…and quite frankly, more patients in the US need to be looked at to prove efficacy and safety.' Richard Pazdur, MD, director of the FDA's Oncology Center of Excellence, said these issues in STARGLO aren't uncommon. 'Unfortunately, if you take a look at all the oncology trials that come to us, only about 20% of the population is derived from the United States. We'd like to understand the reasons why sites are not enrolling in the United States. Potentially, that could be lack of interest because many times the control arms are not appropriate for a US population,' he said. 'This is going to be an area that the Oncology Center of Excellence is looking at quite closely. People are developing drugs for marketing in the United States, so it should address our interest here in the United States,' he said. A Win for DARA SC ODAC also considered the AQUILA trial, which randomized 390 patients with SMM at a high risk for progression to MM to either DARA SC or active monitoring for up to 3 years. At a median follow-up of 65.2 months, the risk for disease progression or death was 51% lower with DARA SC than with active monitoring. At 5 years, PFS was 63.1% with DARA SC and 40.8% with active monitoring, and OS was 93.0% with DARA SC and 86.9% with active monitoring, although the trial was not adequately powered to demonstrate a significant improvement in OS. The positive results were countered by a higher incidence of grade 3/4 treatment emergent adverse events with DARA SC, 40% vs 30%. The FDA's primary concern was that the trial, which was designed almost 10 years ago, used an outdated model to select patients at high risk for progression. With current risk models, only 41% of participants would be categorized as high risk, with 39% considered intermediate risk and 20% as low risk. 'This raises concerns regarding the applicability of the trial results to a population with high-risk SMM, as currently defined,' the FDA said in meeting materials. Also, 'while the trial met its primary PFS endpoint, there is uncertainty in the benefit of delaying progression to [multiple myeloma] in the absence of a significant improvement in OS. Additionally, the observed difference in progression was primarily due to differences observed in the biochemical or lab parameters,' not the onset of symptomatic disease, the FDA said. Not all high-risk patients progress to MM, so the agency also had concerns about unnecessary treatment — particularly with the elevated risk for serious and high-grade adverse events with daratumumab. 'Given the limitations of the clinical meaningfulness of the efficacy findings and the toxicity observed with 3 years of treatment with Dara SC, there is uncertainty regarding the benefit-risk profile of Dara SC for patients with high-risk SMM,' the agency said. Johnson and Johnson countered by emphasizing that all of the trials endpoints are positive, and that without an approved medication for SMM, patients are left powerless as they wait for a MM to emerge, something a commenter likened to 'sitting on a ticking time bomb.' Vincent Rajkumar, MD, myeloma specialist at the Mayo Clinic in Rochester, Minnesota, presenting on behalf of the company, also caught the attention of panelists when he said that high-risk SMM isn't simply a benign precursor to MM, but rather cancer in itself, raising the stakes for early intervention. 'It is asymptomatic, but not premalignant. It is cancer. Genomically, [it is] indistinguishable from multiple myeloma,' he said. In the end, the company's arguments won the day. ODAC voted 6 to 2 that AQUILA provide sufficient evidence to support a favorable risk-benefit profile for DARA SC for SMM. 'The shift for me was thinking of smoldering multiple myeloma as a malignancy and allowing the physician and patient to look at this data and intervene earlier if they so choose,' McKean said. Another committee member, Christopher Lieu, MD, gastrointestinal medical oncologist at the University of Colorado Cancer Center, Aurora, Colorado, agreed. 'I really want patients and providers to have the option to discuss this, to have the benefit-risk discussion. The conversation includes the fact that there are toxicities from this drug; that there's a chance that you can prevent a life-altering fracture; that you might be able to prevent or delay at least the onset of treatment; that you might be able to delay or prevent an organ damage. I think that that is a conversation that I want patients and providers to have the option to have,' Lieu said. However, this is going to lead to overtreatment. There has to be a predictive biomarker or some type of risk stratification to refine this high-risk group,' he said. The FDA usually follows the advice of its advisory committees.
Yahoo
12-05-2025
- Business
- Yahoo
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025; assuming approval, commercial launch to immediately follow with product availability in July Oncologic Drugs Advisory Committee scheduled for May 21, 2025 JELMYTO® achieved net product sales of $20.3 million in Q1 2025, compared with $18.8 million in Q1 2024, driven by underlying demand growth of 12% $200.4 million in cash, cash equivalents and marketable securities as of March 31, 2025 Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., May 12, 2025--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2025, and provided an overview of recent developments. "We are entering a pivotal and exciting period for UroGen as we approach the anticipated FDA approval of our lead pipeline product, UGN-102, in June for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer," said Liz Barrett, President and Chief Executive Officer of UroGen. "This milestone has the potential to mark the first major advancement in treatment for this patient population in decades, delivering a much-needed novel and innovative treatment option that may offer meaningful disease and treatment-free intervals. With momentum building across the organization, we are entering the final phase of launch readiness. If approved, UGN-102 represents a significant commercial opportunity, with a total addressable market of over $5 billion. Backed by a strong balance sheet and a growing pipeline, we are well-positioned to build a long-term, sustainable growth company. We remain steadfast in our mission to transform the treatment paradigm in uro-oncology and see a great opportunity to advance patient care and deliver value for shareholders." Q1 2025 and Recent Business Highlights: UGN-102 (mitomycin) for intravesical solution UroGen's New Drug Application (NDA) for investigational drug UGN-102 (mitomycin) for intravesical solution as a treatment for recurrent low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC), is currently under review at the U.S. Food and Drug Administration (FDA). The FDA granted a Prescription Drug User Fee Act (PDUFA) target action date of June 13, 2025. The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) meeting on May 21, 2025 to discuss the UGN-102 NDA. Updated 18-month Duration of Response (DOR) data from the Phase 3 ENVISION trial evaluating UGN-102 in patients with recurrent LG-IR-NMIBC were featured in a podium presentation by Dr. Sandip Prasad at the American Urological Association (AUA) 2025 Annual Meeting on April 26 in Las Vegas. The data are consistent with prior Kaplan-Meier estimates, with the probability of remaining in complete response (CR) of 80.6% (95% CI: 74.0, 85.7) at 18-months after achieving CR at 3 months (N=101) compared to 82.5% (95% CI: 76.1, 87.3) at 12-months after 3-month CR (N=146). Median follow-up time at 18 months was 18.7 months after the three-month CR. The results of a patient reported outcomes analysis from three UGN-102 studies (OPTIMA II, ATLAS and ENVISION) were presented in a poster at the AUA meeting. The results showed that UGN-102 did not have a negative impact on symptom burden, patient function, or quality of life. Long-term outcomes of the OPTIMA II LT study of UGN-102 were also presented at the meeting and demonstrated median DOR of 24.2 months (95% CI 9.72, 47.18) with a median follow-up time of 33.6 months (95% CI 10.78, 42.94) in the 41 patients who achieved a CR in the parent study. Results from a post-hoc sub-analysis of the ENVISION trial, showing that tumor burden and the number of tumors did not significantly affect the CR rate or durability of response for patients treated with UGN-102, were presented at the ASCO Genitourinary Cancers Symposium (ASCO-GU 2025) in February 2025. Results from the ENVISION trial were published in the February 2025 issue of The Journal of Urology. JELMYTO (mitomycin) for pyelocalyceal solution in low-grade upper tract urothelial cancer (LG-UTUC) Generated net product revenue of $20.3 million in the quarter ended March 31, 2025, an increase of 8% over the $18.8 million reported for the same quarter in 2024. Underlying demand grew by 12% year-over-year. A poster featuring long-term outcomes of patients with recurrent and new-onset LG-UTUC who achieved CR in the Phase 3 trial of JELMYTO was presented at AUA 2025. As previously reported, the median DOR of all patients achieving CR in the JELMYTO Phase 3 study was 47.8 months, irrespective of whether their cancer was new onset or recurrent. A long-term study on JELMYTO titled, "Durability of Response of UGN-101: Longitudinal Follow-Up of Multicenter Study," was published online in Urologic Oncology: Seminars and Investigations in January 2025. The results showed 68% recurrence-free survival rate at three years across a broad patient population with LG-UTUC. UGN-301 (zalifrelimab) intravesical solution, an anti-CTLA4 antibody for use in high-grade non-muscle invasive bladder cancer (NMIBC) Enrollment is complete in the multi-arm dose escalation Phase 1 clinical study of UGN-301 in patients with high-grade NMIBC, alone and in combination with fixed dose UGN-201 or gemcitabine. The investigational treatments demonstrated an acceptable safety profile and were generally well tolerated across dose levels. Responses were observed in both monotherapy and combination therapy arms, and patient follow-up is ongoing to further assess the durability of these responses. Next-generation investigational oncolytic virus UGN-501 (ICVB-1042) In February 2025, UroGen expanded its nonclinical oncology portfolio with the purchase of product candidate UGN-501 from IconOVir Bio, Inc (IconOVir). UGN-501 is a potent and fast-replicating investigational next generation oncolytic virus therapy, being developed as a locally administered treatment for bladder cancer and other specialty cancers. UroGen hosted a webinar to discuss UGN-501 (ICVB-1042) on February 20, 2025, and a replay can be accessed on the Company's website here. Next-generation novel mitomycin-based formulation for urothelial cancers Enrollment is ongoing in the Phase 3 UTOPIA clinical trial of investigational drug UGN-103 (mitomycin) for intravesical solution in patients with LG-IR-NMIBC and enrollment is expected to be completed by mid-2025. UGN-103 is a next generation product that combines UroGen's RTGel® technology with a novel mitomycin formulation licensed from medac GmbH. UGN-103 is planned to follow the potential FDA approval and launch of UGN-102 for recurrent LG-IR-NMIBC. To learn more about the UTOPIA trial, refer to UroGen plans to initiate a Phase 3 trial to explore the safety and efficacy of UGN-104 by mid-2025. UGN-104 is a next generation investigational product for LG-UTUC. First quarter 2025 Financial Results JELMYTO Revenue: JELMYTO net product revenues were $20.3 million for the three months ended March 31, 2025, compared with $18.8 million for the same quarter of 2024. Year-over-year revenue growth of 8% was driven by underlying demand growth of 12%, partially offset by higher 340B chargebacks. R&D Expenses: R&D expenses for the first quarter of 2025 were $19.9 million, including non-cash share-based compensation expense of $0.6 million as compared to $15.5 million, including non-cash share-based compensation expense of $0.5 million, for the same period in 2024. The increase in R&D expenses of $4.4 million was primarily driven by the equity consideration issued to IconOVir for the acquisition of UGN-501 (ICVB-1042) which was expensed in the first quarter of 2025, higher manufacturing costs, and costs associated with the Phase 3 UTOPIA trial for UGN-103, partially offset by lower clinical trial costs and regulatory expenses in connection with UGN-102. SG&A Expenses: SG&A expenses for the first quarter of 2025 were $35.0 million, including non-cash share-based compensation expense of $2.5 million. This compares to $27.3 million, including non-cash share-based compensation expense of $2.2 million, for the same period in 2024. The increase in SG&A expenses of $7.7 million was primarily driven by UGN-102 commercial preparation activities. Financing on Prepaid Forward Obligation: UroGen reported non-cash financing expense related to the prepaid forward obligation to RTW Investments of $4.6 million in the first quarter of 2025, compared to $5.7 million in the same period in 2024. The decrease was primarily driven by changes in underlying assumptions for remeasuring the effective rate. Interest Expense on Long-Term Debt: Interest expense related to the $125 million term loan facility with funds managed by Pharmakon Advisors was $4.1 million in the first quarter of 2025, compared to $2.4 million in the same period in 2024. The increase was primarily attributable to the interest expense on the third tranche of the loan that was funded in September 2024. Net Loss: UroGen reported a net loss of $43.8 million or ($0.92) per basic and diluted share in the first quarter of 2025 compared with a net loss of $32.3 million or ($0.87) per basic and diluted share in the same period in 2024. Cash and Equivalents: As of March 31, 2025, cash, cash equivalents and marketable securities totaled $200.4 million. For further details on the Company's financials, refer to Form 10-Q, filed with the SEC. 2025 JELMYTO Revenue and Company Operating Expense Guidance: Guidance for full-year 2025 net product revenues for JELMYTO remains unchanged and is expected to be in the range of $94 to $98 million. This implies a year-over-year growth rate of approximately 8% to 12% over the $87.4 million in demand driven JELMYTO sales in 2024, which excludes the $3.0 million in CREATES Act sales reported in 2024. Continue to expect full-year 2025 operating expenses to be in the range of $215 to $225 million, including non-cash share-based compensation expense of $11 million to $14 million. Conference Call & Webcast Information: Members of UroGen's management team will host a live conference call and webcast today at 10:00 AM Eastern Time to review UroGen's financial results and provide a general business update. The live webcast can be accessed by visiting the Investors section of the Company's website at Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. UROGEN PHARMA LTD. SELECTED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands) (Unaudited) March 31, 2025 December 31, 2024 Cash and cash equivalents and marketable securities $ 200,405 $ 241,707 Total assets $ 247,618 $ 285,711 Total liabilities $ 294,076 $ 294,514 Total shareholders' deficit $ (46,458) $ (8,803) UROGEN PHARMA LTD. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (U.S. dollars in thousands, except share and per share data) (Unaudited) Three months ended March 31, 2025 2024 Revenue $ 20,254 $ 18,781 Cost of revenue 2,330 1,728 Gross profit 17,924 17,053 Operating expenses: Research and development expenses 19,871 15,494 Selling, general and administrative expenses 34,967 27,299 Total operating expenses 54,838 42,793 Operating loss (36,914) (25,740) Financing on prepaid forward obligation (4,583) (5,660) Interest expense on long-term debt (4,068) (2,447) Interest and other income, net 2,114 1,615 Loss before income taxes $ (43,451) $ (32,232) Income tax expense (392) (54) Net loss $ (43,843) $ (32,286) Net loss per ordinary share, basic and diluted $ (0.92) $ (0.87) Weighted average shares outstanding, basic and diluted 47,422,119 37,059,186 About JELMYTO JELMYTO® (mitomycin) for pyelocalyceal solution is a mitomycin-containing reverse thermal gel containing 4 mg mitomycin per mL gel indicated for the treatment of adult patients with LG-UTUC. It is recommended for primary treatment of biopsy-proven LG-UTUC in patients deemed appropriate candidates for renal-sparing therapy. JELMYTO is a viscous liquid when cooled and becomes a semi-solid gel at body temperature. The drug slowly dissolves over four to six hours after instillation and is removed from the urinary tract by normal urine flow and voiding. It is approved for administration in a retrograde manner via ureteral catheter or antegrade through nephrostomy tube. The delivery system allows the initial liquid to coat and conform to the upper urinary tract anatomy. The eventual semisolid gel allows for chemoablative therapy to remain in the collecting system for four to six hours without immediately being diluted or washed away by urine flow. APPROVED USE FOR JELMYTO JELMYTO® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC). IMPORTANT SAFETY INFORMATION You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract. Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you: are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose. Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose. Tell your healthcare provider if you take water pills (diuretic). How will I receive JELMYTO? Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment. You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses. JELMYTO is given to your kidney through a tube called a catheter. During treatment with JELMYTO, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving JELMYTO: JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. JELMYTO may cause serious side effects, including: Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO. Bone marrow problems. JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO. The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1‑800‑FDA‑1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see JELMYTO Full Prescribing Information, including the Patient Information, for additional information. About Upper Tract Urothelial Cancer (UTUC) Urothelial cancer is the ninth most common cancer globally and the eighth most lethal neoplasm in men in the U.S. Between five percent and ten percent of primary urothelial cancers originate in the ureter or renal pelvis and are collectively referred to as UTUC. In the U.S., there are approximately 6,000 - 7,000 new or recurrent LG-UTUC patients annually. Most cases are diagnosed in patients over 70 years old, and these older patients often face comorbidities. There are limited treatment options for UTUC, with the most common being endoscopic surgery or nephroureterectomy (removal of the entire kidney and ureter). Treatment with endoscopic surgery can be associated with a high rate of recurrence and relapse. About UGN-102 UGN-102 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, currently in Phase 3 development for the treatment of recurrent LG-IR-NMIBC. Utilizing UroGen's proprietary RTGel® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting by a trained healthcare professional. UroGen completed the submission of a rolling NDA in August 2024, ahead of schedule. The FDA accepted the NDA for UGN-102 and assigned a PDUFA goal date of June 13, 2025. About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with recurrent low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit to learn more or follow us on X (Twitter), @UroGenPharma. Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: UroGen's UGN-102 NDA submission, scheduled ODAC meeting, and expected PDUFA goal date; the potential for UGN-102 to be the first major advancement in treatment recurrent LG-IR-NMIBC in decades; the estimated patient population, demographics, and market opportunities for LG-IR-NMIBC and UTUC; the belief that UroGen is well-positioned for sustained growth; conclusions from the ENVISION data; the potential applications of UGN-501 in treating bladder cancer as well as other types of cancers; the timing for enrollment completion in the Phase 3 UTOPIA clinical trial of UGN-103; plans for UGN-103 to follow the potential FDA approval and launch of UGN-102; the timing for the planned Phase 3 trial to explore the safety and efficacy of UGN-104 in the first half of 2025; 2025 financial guidance; the potential of UroGen's proprietary RTGel technology to improve therapeutic profiles of existing drugs; and UroGen's sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as "anticipate," "assume," "can," "expect," "if," "imply," "may," "plan," "potential," "remain," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: preliminary results may not be indicative of results that may be observed in the future; the timing and success of clinical trials and potential safety and other complications thereof; unforeseen delays that may impact the timing of progressing clinical trials and reporting data; the ability to obtain regulatory approval within the timeframe expected, or at all; the outcome of the ODAC meeting is uncertain and it is possible that the ODAC meeting will have an adverse or split recommendation with respect to UGN-102; even if the ODAC recommends the approval of UGN-102, the FDA is not bound by the ODAC's recommendation; the PDUFA goal date may be delayed due to various factors outside UroGen's control; the ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights; the ability to obtain and maintain regulatory approval within the timeframe expected, or at all; complications associated with commercialization activities; the labeling for any approved product; competition in UroGen's industry; the scope, progress and expansion of developing and commercializing UroGen's product and product candidates; the size and growth of the market(s) for UroGen's product and product candidates and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen's ability to attract or retain key management, members of the board of directors and personnel; UroGen's RTGel technology may not perform as expected; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; and UroGen's financial condition and need for additional capital in the future. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 10, 2025, as well as in the Risk Factors section of UroGen's Quarterly Report on Form 10-Q being filed with the SEC later today. The events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release. View source version on Contacts INVESTOR CONTACT:Vincent PerroneSenior Director, Investor 609-460-3588 ext. 1093 MEDIA CONTACT:Cindy RomanoDirector, Corporate 609-460-3583 ext. 1083 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
